New drug cocktail aims to starve pancreatic tumors
NCT ID NCT05034627
First seen Oct 31, 2025 · Last updated Apr 29, 2026 · Updated 34 times
Summary
This early-stage trial tests a combination of two drugs—calaspargase and cobimetinib—in about 15 people with advanced pancreatic cancer that has spread. Calaspargase works by cutting off a key nutrient that cancer cells need to grow, while cobimetinib blocks a protein that helps them survive. The goal is to find the safest dose and see if this approach can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.